Transplantation· 2012Q1
De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy
- 249citations
- Q1SCImago
- 2012year
Short summary
Developing de novo DQ donor-specific antibodies (DSAbs) after kidney transplant significantly increases the risk of antibody-mediated rejection (AMR), transplant glomerulopathy, and allograft loss (18.2% of patients developed DSAbs, with 54.3% of those having DQ DSAbs).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Transplantation
TransplantationMedicine